Product Description
SHetA2 reduced cyclin D1 to greater extents in cancer compared to non-cancer cell cultures.
Mechanisms of Action: HSP70 Inhibitor
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: University of Oklahoma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Okgyn1 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-11-01 |